Inovio Jumps 300% After FDA Approves First Commercial Product Voceryq
INO has more than doubled off its 52-week low of $0.563 on elevated volume (12× avg).
Summary
The FDA granted accelerated approval to Inovio's INO-3107, now branded Voceryq, an immunotherapy to reduce the frequency of surgery in adults with recurrent respiratory papillomatosis (RRP) — the company's first-ever approved product. Shares are up roughly 300% on the news, taking the stock to about $2.30 from a pre-approval level near $0.58. Inovio expects VOCERYQ to be available to order and ship in about 60 days, with full field deployment in Q1 2027, and the FDA requires a confirmatory study draft protocol by end of 2026. The move matters because Inovio entered the approval with a going concern warning and cash runway only into late Q1 2027, so a commercial launch is now the company's funding story, not just a pipeline milestone. The approval follows the October 20th $80.4M Pennsylvania court judgment against VGXI and GeneOne, which added cash but not revenue. Watch the launch economics and any financing tied to commercialization — the $300M shelf filed in July is the likely funding route.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Inovio expects VOCERYQ available to order and ship in about 60 days, with full field deployment in Q1 2027; FDA requires a confirmatory study draft protocol by end of 2026.
At the time of this announcement, INO was trading at $2.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $62.3M. The 52-week trading range was $0.56 to $2.72. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Seeking Alpha.